Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 May 24;326(7399):1115.
doi: 10.1136/bmj.326.7399.1115.

Stepping down inhaled corticosteroids in asthma: randomised controlled trial

Gillian Hawkins  1 , Alex D McMahon, Sara Twaddle, Stuart F Wood, Ian Ford, Neil C Thomson
Affiliations
Clinical Trial

Stepping down inhaled corticosteroids in asthma: randomised controlled trial

Gillian Hawkins et al. BMJ. .

Abstract

Objectives: To determine whether the dose of inhaled corticosteroids can be stepped down in patients with chronic stable asthma while maintaining control.

Design: One year, randomised controlled, double blind, parallel group trial.

Setting: General practices throughout western and central Scotland.

Participants: 259 adult patients with asthma receiving regular treatment with inhaled corticosteroids at high dose (mean dose 1430 microg beclomethasone dipropionate).

Interventions: Participants were allocated to receive either no alteration to their dose of inhaled corticosteroid (control) or a 50% reduction in their dose if they met criteria for stable asthma (stepdown).

Main outcome measures: Comparison of asthma exacerbation rates, asthma related visits to general practice and hospital, health status measures, and corticosteroid dosage between the two groups.

Results: The proportions of subjects with asthma exacerbations were not significantly different (stepdown 31%, control 26%, P=0.354). Similarly, the numbers of visits to general practice or hospital and the disease specific and generic measures of health status over the one year period were not significantly different. On average the stepdown group received 348 microg (95% confidence interval 202 microg to 494 microg) of beclomethasone dipropionate less per day than the controls (a difference of 25%), with no difference in the annual dose of oral corticosteroids between the two treatment regimens.

Conclusions: By adopting a stepdown approach to the use of inhaled steroids at high doses in asthma a reduction in the dose can be achieved without compromising asthma control.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of participants
See this image and copyright information in PMC

Comment in

References

    1. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157(suppl): S1-S53. - PubMed
    1. British Guidelines on the Management of Asthma. Thorax 2003;58(suppl 1): S1-S96.
    1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda (MD): NHLBI/WHO Workshop Report 1995. (Publication no 95-3659.)
    1. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 1999;159: 941-55. - PubMed
    1. Haahtela T, Jarvinnen M, Kava T, Kiviranta K, Sirkka K, Lehtonen K, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331: 700-5. - PubMed

Publication types